Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
-- | -- | -- | -- | -- |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
CRIS
Curis, Inc.
|
$3.2M | -$0.43 | -2.86% | -65.51% | $14.00 |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$39.00 | -- | -94.17% | $4.0000 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$64.20 | -- | $204.6M | 18.45x | $0.31 | 1.91% | 5.40x |
|
AGEN
Agenus, Inc.
|
$2.98 | $12.33 | $101.3M | -- | $0.00 | 0% | 0.75x |
|
CRIS
Curis, Inc.
|
$1.06 | $14.00 | $13.7M | -- | $0.00 | 0% | 1.01x |
|
LADX
LadRx Corp.
|
$0.10 | -- | $51.2K | 0.84x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.27 | $5.50 | $37.3M | -- | $0.00 | 0% | 4.35x |
|
WINT
Windtree Therapeutics, Inc.
|
$0.0091 | $4.0000 | $306.8K | 0.00x | $0.00 | 0% | 0.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
-- | 1.050 | -- | 34.36x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.019 | 285.06% | 0.03x |
|
CRIS
Curis, Inc.
|
192.35% | 2.868 | 144.76% | 0.62x |
|
LADX
LadRx Corp.
|
-- | 2.863 | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WINT
Windtree Therapeutics, Inc.
|
974.23% | 2.926 | 568.87% | 0.01x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$4.7M | $2.4M | 9.55% | 9.57% | 27% | $3.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
-$360K | -$3.8M | -320.18% | -760.4% | -- | -$6.4M |
Agenus, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of -116.82%. Utah Medical Products, Inc.'s return on equity of 9.57% beat Agenus, Inc.'s return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
52.31% | $0.80 | $119.3M |
|
AGEN
Agenus, Inc.
|
87.85% | $1.94 | $60.1M |
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 313.87%. Given that Agenus, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Agenus, Inc. is more attractive than Utah Medical Products, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0 | 0 | 0 |
|
AGEN
Agenus, Inc.
|
2 | 1 | 0 |
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.619, suggesting its more volatile than the S&P 500 by 61.86%.
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Utah Medical Products, Inc. quarterly revenues are $9M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Utah Medical Products, Inc.'s net income of $2.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 0.75x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
5.40x | 18.45x | $9M | $2.6M |
|
AGEN
Agenus, Inc.
|
0.75x | -- | $30.2M | $63.9M |
Curis, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of -243.36%. Utah Medical Products, Inc.'s return on equity of 9.57% beat Curis, Inc.'s return on equity of -461.34%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
52.31% | $0.80 | $119.3M |
|
CRIS
Curis, Inc.
|
98.52% | -$0.49 | $15.9M |
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Curis, Inc. has an analysts' consensus of $14.00 which suggests that it could grow by 1220.76%. Given that Curis, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Curis, Inc. is more attractive than Utah Medical Products, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0 | 0 | 0 |
|
CRIS
Curis, Inc.
|
4 | 0 | 0 |
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 3.078, suggesting its more volatile than the S&P 500 by 207.818%.
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 1.01x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
5.40x | 18.45x | $9M | $2.6M |
|
CRIS
Curis, Inc.
|
1.01x | -- | $3.2M | -$7.7M |
LadRx Corp. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of --. Utah Medical Products, Inc.'s return on equity of 9.57% beat LadRx Corp.'s return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
52.31% | $0.80 | $119.3M |
|
LADX
LadRx Corp.
|
-- | -$1.45 | -- |
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 434682.61%. Given that LadRx Corp. has higher upside potential than Utah Medical Products, Inc., analysts believe LadRx Corp. is more attractive than Utah Medical Products, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0 | 0 | 0 |
|
LADX
LadRx Corp.
|
0 | 0 | 0 |
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.464, suggesting its less volatile than the S&P 500 by 53.583%.
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than LadRx Corp. quarterly revenues of --. Utah Medical Products, Inc.'s net income of $2.6M is higher than LadRx Corp.'s net income of -$719.3K. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
5.40x | 18.45x | $9M | $2.6M |
|
LADX
LadRx Corp.
|
-- | 0.84x | -- | -$719.3K |
Plus Therapeutics, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of -316.61%. Utah Medical Products, Inc.'s return on equity of 9.57% beat Plus Therapeutics, Inc.'s return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
52.31% | $0.80 | $119.3M |
|
PSTV
Plus Therapeutics, Inc.
|
93.84% | -$0.04 | $5.1M |
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1928.02%. Given that Plus Therapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Utah Medical Products, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0 | 0 | 0 |
|
PSTV
Plus Therapeutics, Inc.
|
4 | 0 | 0 |
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 4.35x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
5.40x | 18.45x | $9M | $2.6M |
|
PSTV
Plus Therapeutics, Inc.
|
4.35x | -- | $1.4M | -$4.4M |
Windtree Therapeutics, Inc. has a net margin of 28.36% compared to Utah Medical Products, Inc.'s net margin of --. Utah Medical Products, Inc.'s return on equity of 9.57% beat Windtree Therapeutics, Inc.'s return on equity of -760.4%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
52.31% | $0.80 | $119.3M |
|
WINT
Windtree Therapeutics, Inc.
|
-- | -$1.08 | $1.3M |
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Windtree Therapeutics, Inc. has an analysts' consensus of $4.0000 which suggests that it could grow by 43856.04%. Given that Windtree Therapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Windtree Therapeutics, Inc. is more attractive than Utah Medical Products, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0 | 0 | 0 |
|
WINT
Windtree Therapeutics, Inc.
|
0 | 0 | 0 |
Utah Medical Products, Inc. has a beta of 0.342, which suggesting that the stock is 65.824% less volatile than S&P 500. In comparison Windtree Therapeutics, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.733%.
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 1.91%. Windtree Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 35.17% of its earnings as a dividend. Windtree Therapeutics, Inc. pays out 36.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Utah Medical Products, Inc. quarterly revenues are $9M, which are larger than Windtree Therapeutics, Inc. quarterly revenues of --. Utah Medical Products, Inc.'s net income of $2.6M is higher than Windtree Therapeutics, Inc.'s net income of -$28.1M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 18.45x while Windtree Therapeutics, Inc.'s PE ratio is 0.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 5.40x versus 0.26x for Windtree Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
5.40x | 18.45x | $9M | $2.6M |
|
WINT
Windtree Therapeutics, Inc.
|
0.26x | 0.00x | -- | -$28.1M |
Signup to receive the latest stock alerts
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Though certainly less well-known than the huge tech businesses that…
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Market Cap: $4.6T
P/E Ratio: 65x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 29x
Teradata Corp. [TDC] is down 11.64% over the past day.
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.